Cycloserine/lurasidone
| Combination of | |
|---|---|
| Cycloserine | NMDA receptor modulator |
| Lurasidone | Atypical antipsychotic |
| Clinical data | |
| Other names | Cyclurad |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status | |
Cycloserine/lurasidone (proposed brand name Cyclurad) is a combination formulation of cycloserine (D-cycloserine), a partial agonist of the glycine site of the NMDA receptor, and lurasidone, an atypical antipsychotic, which is under development for the treatment of bipolar depression by NeuroRx.[1]
References
- ^ Kantrowitz, Joshua T.; Halberstam, Batsheva; Gangwisch, James (2015). "Single-Dose Ketamine Followed by Daily d-Cycloserine in Treatment-Resistant Bipolar Depression". The Journal of Clinical Psychiatry: 737–738. doi:10.4088/JCP.14l09527. ISSN 0160-6689.
External links
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |